MAPP – PDUFA Trade Strategy

Quick take on some upcoming FDA decisions and clinical data

A few comments to highlight some upcoming data or PDUFA events. Threshold Pharmaceuticals (NASDAQ: THLD) has been quite the stock the past few months after landing a partnership with Merck.

Quick take on some upcoming catalysts

With Gilead’s (NASDAQ: GILD) recent announcement about the 7977 data(100% RVR, 25/25 in genotype 1 patients so far) should have Idenix(NASDAQ: IDIX) and Achillion(NASDAQ: ACHN) investors thinking hard about the.

AMGN, REGN, MNTA & THLD – Quick Updates

Below are some brief note on about a dozen stocks that we felt compelled to brief subscribers on. Today, the briefing documents and panel attendees list for Amgen’s (NASDAQ: AMGN).

Trade Ideas for some upcoming catalysts

We wanted to throw out some trading ideas for some stocks that we are following, but may not necessarily get full write-ups on in time. Ideally, we will have research.

AMLN – Neutral/Bearish Trade for PDUFA

Analyst Notes: These kind of things are troubling because of the cardiovascular nature of the FDA’s qualms. However, give it a 50% success probability “In the second CRL, Amylin and.

ACHN & ARIA – Time To Take Some Profits

Both Achillion and Ariad hit 52-week highs today after running up on positive news. While we continue to believe the companies will be successful, we also believe the stocks are.

BPAX: Trade Idea for LibiGel Phase 3 Data (#2)

Video: http://content.screencast.com/users/moomoomoomoo1/folders/Trades/media/880fdea6-34fb-4a86-ba61-5866e40d6f30/$BPAX120811.swf&blurover=false

AFFY – AdCom Trading Strategies (#2)

Unable to display content. Adobe Flash is required.

AFFY – AdCom Trading Strategies (#1)

Unable to display content. Adobe Flash is required.

ALXA – AdCom Trading Idea (#1)

Unable to display content. Adobe Flash is required.

ONXX – Trade Idea

Onyx Pharmaceuticals(ONXX) submitted their NDA for Carfilzomib to the FDA under the accelerated approval process on 9/28/11 and are seeking a 6-month priority review. At the earliest, they could be.

AMRN – Put Sale

Unable to display content. Adobe Flash is required.

BPAX – Trade Ideas for LibiGel Phase III Data

Unable to display content. Adobe Flash is required.

TSPT – Put Ratio (Part 2)

Video: http://content.screencast.com/users/biotechtraderHB/folders/Default/media/2acf5e03-4146-4f98-b857-f005296c5ffc/$TSPT111411a.swf&blurover=false

TSPT – Neutral Trade Idea (Part 1)

Video: http://content.screencast.com/users/biotechtraderHB/folders/Default/media/aec06074-e5c3-4827-8aeb-1d9a9b38b1b9/$TSPT111411.swf

ALIM & PSDV – Trade Review

We fully expected that pSivida(NASDAQ: PSDV) and Alimera Sciences(NASDAQ:ALIM) will receive another Complete Response Letter for ILUVIEN in the treatment of diabetic macular edema (DME). We see little reason for.

INHX – Trade Idea

Video: http://content.screencast.com/users/biotechtraderHB/folders/Default/media/e7f5888c-ae53-412d-ad9e-36eee29a425b/$INHX110911.swf Analyst Notes: INHX showed only 7 day viral reduction data, which has not been shown to be highly correlated to a sustained viral response. What we want to.

INCY – PDUFA Trade Note

Incyte Pharmaceuticals is awaiting FDA approval of its lead compound Ruxolitinib (INCB18424) for the treatment of Myelofibrosis (MF) with an expected decision date on December 3, 2011.  Our analysis suggests.

Trade Strategy: Approaching Catalysts

Its end of year 2011 and there are a large quantity of trading opportunities approaching. On the docket: $ALIM – PDUFA (NOV 12, 2011) $SPPI – PDUFA (NOV 20, 2011).

Browsing 31 / 219 articles